A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to viral infections, shows promising results in patients with relapsed or refractory natural killer/T-ce…
A tiny molecule called a nanobody may succeed where today’s cancer drugs often fail, according to University of Hawaiʻi at Mānoa researcher Stefan Moisyadi, who has been refining the concept for nearly a decade.
Many advanced cancers develop resistance to treatment and become highly aggressive, often leaving patients with limited treatment options. In some cancers, including lung, pancreatic and prostate tumors, a key driver of treatment resistance and metasta…
The aim of immunotherapy strategies is to leverage cells in the patient’s own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm successfully stimulated an effective anti-tumor immune respon…
A research team at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has discovered that certain dietary fatty acids can supercharge the human immune system’s ability to fight cancer. The team found that a healthy fatty acid found in …
Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to the liver. Despite progress in surgical therapies ai…
A multi-institutional study from the Accelerating GBM Therapies Through Serial Biopsies TeamLab, led by investigators from the Mass General Brigham Cancer Institute, found that serially testing tumor samples can help detect when a cancer treatment is a…
Scientists at Virginia Tech’s Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging trends in cancer immunotherapy with back-to-back review articles published in Nature Cancer and Trends in Cancer that look at how n…
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.
UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting cancer-associated fibroblasts (apCAFs) that appear to support the survival and growth of malignant tumors. Their findings, reported…
